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Cancer is characterized by pervasive epigenetic alterations with enhancer dysfunction
orchestrating the aberrant cancer transcriptional programs and transcriptional dependencies.
Here, we epigenetically characterize human colorectal cancer (CRC) using de novo chromatin
state discovery on a library of different patient-derived organoids. By exploring this resource,
we unveil a tumor-specific deregulated enhancerome that is cancer cell-intrinsic and inde-
pendent of interpatient heterogeneity. We show that the transcriptional coactivators YAP/
TAZ act as key regulators of the conserved CRC gained enhancers. The same YAP/TAZ-
bound enhancers display active chromatin profiles across diverse human tumors, highlighting
a pan-cancer epigenetic rewiring which at single-cell level distinguishes malignant from
normal cell populations. YAP/TAZ inhibition in established tumor organoids causes extensive
cell death unveiling their essential role in tumor maintenance. This work indicates a common
layer of YAP/TAZ-fueled enhancer reprogramming that is key for the cancer cell state and
can be exploited for the development of improved therapeutic avenues.
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Colorectal cancer (CRC) features amongst the three mostwidely spread malignancies worldwide1, characterized bydiverse clinical phenotypes and responses to current
treatments. Indeed, one of the most prominent CRC features is its
considerable interpatient heterogeneity. Recent years have seen
numerous efforts to classify genetically and phenotypically
diverse CRC tumors into distinct molecular subtypes based on
gene expression profiling2,3. These studies highlight the chal-
lenges in identifying a consensus molecular classification system
and the urgent need to re-assess interpatient variability through
the prism of a shared regulatory architecture.
Epigenetic deregulation has emerged as a paradigm of cancer
biology that underlies the hallmarks of cancer cells4. Global
changes in DNA methylation, chromatin states, and cis-reg-
ulatory elements, as well as genetic aberrations in chromatin
proteins characterize more than 50% of human cancers5.
Enhancers, identified with precision via global mapping of his-
tone modifications, contribute to cell reprogramming towards
tumor growth and metastasis6,7, rendering enhancer dysfunction
a promising biomarker of diagnosis and a potential therapeutic
target. Indeed the deregulated enhancerome has attracted atten-
tion due to its role in the establishment and maintenance of
transcriptional addiction8, a state of tumor cell dependence on
transcription factors and chromatin regulators for sustained
uncontrolled proliferation.
In this line of investigation, many questions remain under-
explored: what is the enhancer repertoire activated in cancer cells
and is it tumor-specific or, perhaps, is there a common layer of
epigenetic deregulation across diverse human malignancies? Sys-
tematic studies of chromatin modifications in cancer9 and seminal
reports on the molecular mechanisms at the roots of transcrip-
tional addiction10 have started to emerge. Nevertheless, defining
the chromatin states that characterize a human pathology remains
a challenge, partly due to the limited amount of cells available
from primary tumors. Another critical issue in investigating the
epigenetic profiles of individual tumors is the use of appropriate
research platforms that capture the cancer-cell intrinsic profiles11.
Three-dimensional, self-organizing organoid cultures represent
such powerful ex vivo models that, contrary to cell lines, recapi-
tulate the overall architecture and functional features of the tissues
from which they originate12. In this context, patient-derived
organoids (PDOs) of CRC capture the histological and molecular
heterogeneity of pure cancer cells13 offering an amenable tool to
decipher the underlying regulatory networks of primary tumors.
Here, we seek to identify the common epigenetic blueprints
that may affect the cellular events mediating cancer and provide
leads on the master regulators that orchestrate the transcriptional
deregulation, upon which cancer cells depend. Leveraging the
organoid technology, we generate a balanced library of hetero-
geneous PDOs from CRC patients and decipher their histone
modification landscapes through de novo chromatin state
reconstruction. Our study provides a detailed resource catalogue
of human CRC-specific epigenetic features, enabling the identi-
fication of a conserved active enhancerome independent of
interpatient tumor heterogeneity. We further highlight the tran-
scriptional coactivators YAP/TAZ as key drivers of the gained
enhancers. Of critical relevance to cancers beyond CRC, we show
that a core of the YAP/TAZ-fueled deregulated enhancers is
consistently active in diverse tumor types crossing the cellular and
molecular divides of tissue of origin, genetic aberrations, and
microenvironmental stimuli.
Results
PDO library as a model of human CRC heterogeneity. With
this background in mind, here we set to characterize the
epigenetic landscape of human CRC. As an overview of our
approach (Fig. 1a), we collected patients’ samples and used them
to generate organoids, performed histopathological and molecular
characterization of organoids validating them as surrogates of the
primary tumors from which they derive, and established their
genome-wide epigenetic landscape (Supplementary Table 1).
In the first step, we obtained a pool of PDOs recapitulating the
molecular heterogeneity of human CRC. For this, we performed
RNA-sequencing (RNA-seq) on the primary tumors (from
surgical resection) and screened them for markers of micro-
satellite instability (MSI) and three recently published gene
expression classifiers2,3,14, contextually generating PDOs from the
same donors. Upon primary tumor analysis, we selected a
collection of 10 PDO lines representing a balanced library that
recapitulates the molecular diversity of the cancer-cell intrinsic
features of human primary CRCs (Fig. 1b).
Next, we validated that our PDOs preserve the histopatholo-
gical and molecular features of primary tumors. We first tested
whether PDOs retained the typical morphological characteristics
and the deregulated architecture of crypt/villus-like structures of
human CRC. By using 3D immunofluorescence whole-mount
analysis, PDOs displayed disorganized epithelial polarity
(EpCAM and F-actin staining respectively, Fig. 1c, first row),
random distribution of cell proliferation (Ki67, Fig. 1c, first row),
displaced localization of enterocytes (FABP1, Fig. 1c, second row)
and presence of cytokeratin 20 positive cells (KRT20, Fig. 1c,
third and fourth rows), recapitulating the common dysplastic
features of human CRC. Interestingly, goblet-specific mucin 2
(MUC2) was absent in most PDOs but massively produced in the
organoid derived from the mucinous adenocarcinoma of patient
13 (Fig. 1c, third and fourth rows), consistent with the
histopathological features of the clinical specimen (Supplemen-
tary Table 1). Upon passaging and long-term culturing, PDOs
retain stable morphology and proliferation rate, and remain
transcriptionally stable (see below and Supplementary Fig. 1a).
Next, we used RNA-seq to compare PDOs with the original
CRCs and normal counterpart from the same patient (Supple-
mentary Data 1). As shown in Fig. 1d, principal component
analysis (PCA) revealed that the transcriptional specificities of
each individual tumor, captured by the second principal
component (PC2), are preserved in its corresponding PDOs
(“Methods” and Supplementary Data 2). Globally, 84% of
expressed genes were concordant between PDOs and tumors
(Fig. 1e, Venn diagram; Supplementary Fig. 1b, c) with the
expression levels across genes being well correlated between PDOs
and primary tumors (Fig. 1e, correlation plot, and Supplementary
Fig. 1d). We then sought to determine which genes are
differentially regulated (induced and repressed) in primary tumor
samples when compared to normal mucosa to identify a CRC
signature and validate its expression in PDOs. Hierarchical
clustering analysis revealed that the CRC signature groups PDOs
together with primary tumors and separates them from normal
colon mucosa (Fig. 1f). Gene set enrichment analysis (GSEA),
using gene signatures of colon carcinoma patients15, further
confirmed that PDOs, when compared to normal tissues, were
enriched in tumor-related genes and depleted in normal mucosa
genes (Fig. 1g). We conclude from these experiments that PDOs
closely recapitulate the cellular and molecular features of their
original CRC. Thus, they offer an abundant physiological resource
of pure cancer cells from primary patient samples that allow us to
focus on the tumor-derived epigenetic profiles uncoupled by those
of non-tumoral cells.
De novo chromatin state discovery in human CRC. Data pre-
sented above establish that our PDO library of different CRC
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subtypes is suitable for deciphering the epigenetic blueprints of
the CRC-cell intrinsic phenotype. Towards this aim, we first
performed a multi-factorial integrative analysis of genome-wide
chromatin immunoprecipitation sequencing (ChIP-seq) for a
core set of five histone modifications (H3K4me3, H3K27ac,
H3K4me1, H3K36me3, and H3K27me3) on all PDOs (Fig. 2a and
Supplementary Data 1). Unsupervised hierarchical clustering and
principal component analyses (Fig. 2b and Supplementary
Fig. 2a) revealed a clear division between histone marks that
represent the major types of chromatin regulation: the repressive
marker H3K27me3, the elongation marker H3K36me3, and the
block of histone marks defining active regulatory regions
(H3K4me3, H3K27ac, and H3K4me1), with ChIP-seq data of
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Notably, the same applied to CRC tumors displaying MSI, typi-
fied by a bewildering amount of genetic aberrations (PDO8 and
PDO11).
To capture the epigenetic layer of CRC complexity in a
systematic manner we exploited machine learning approaches to
perform de novo chromatin state characterization on the
complete ChIP-seq data for the PDOs (Supplementary Data 3).
Using ChromHMM16, we explored the combinatorial patterns of
the five histone marks in an 8-state model and predicted specific
genomic features with high resolution across samples (Fig. 2c and
Supplementary Fig. 2b–d). We defined two promoter states
(“Active TSS” and “Flanking Active TSS”), one weak and two
active enhancer states (“Weak Enhancers”, “Flanking Active
Enhancers”, and “Active Enhancers”), as well as an elongation, a
repressed, and a quiescent state. We then compared the
ChromHMM data with chromatin accessibility for colon
adenocarcinoma (COAD) using ATAC-seq (Assay for Transpo-
sase Accessible Chromatin with high-throughput sequencing)
datasets obtained from The Cancer Genome Atlas (TCGA)17. The
chromatin states identified in PDOs remarkably concur with
chromatin accessibility, with active states displaying the highest
and more inactive regions the lowest ATAC-seq signals,
respectively (Fig. 2d). This provides further support that PDOs
preserve the regulatory networks of primary tumors and thus
represent a faithful resource to investigate the epigenetic land-
scape of CRC. Importantly, the ChromHMM-defined chromatin
states of CRCs constitute a precise atlas of genome-wide
regulatory elements that enables the functional interpretation of
ATAC-seq-defined open chromatin regions.
Human CRCs are characterized by extensive cellular and
molecular heterogeneity. Yet, they also share a considerable
fraction of their transcriptional (Fig. 1f) and epigenetic profiles
(Fig. 2b and Supplementary Fig. 2a). Epigenetic conservation is
shown for FABP1, a marker of enterocytic differentiation
expressed by all PDOs (Fig. 1c, second row); all PDOs display
an active chromatin state at this locus as visualized by the peaks
associated with active histone marks (H3K4me3, H3K27ac, and
H3K4me1) at the promoter and flanking regions (Fig. 2e).
Occurrences of epigenetic intertumor heterogeneity were also
present in our analyses. Regulatory variability across PDOs was
observed in the gene encoding for laminin subunit α-5 (LAMA5)
(Fig. 2f and Supplementary Fig. 3a), a marker of cell adhesion and
migration reported to be involved in metastasis18. Active
transcription in PDO11 is indicated by a ChromHMM profile
that associates with active states around the transcription start site
(TSS) and with an elongation state along the gene body. On the
contrary, LAMA5 is silenced in PDO18 evident by the loss of
H3K36me3 and the accumulation of the H3K27me3 repressive
mark at the promoter and throughout the gene body. The tumor-
specific epigenetic features displayed for LAMA5 in PDOs 11 and
18 are also mirrored at the protein level by 3D immunofluor-
escence analysis (Supplementary Fig. 2e), with active and
repressed chromatin profiles associated to protein presence or
loss, respectively. PDO11 also showed an abundant expression of
the goblet cell-specific marker MUC2 and an active epigenetic
state across the gene (Supplementary Fig. 2e), suggesting a
mucinous phenotype that is consistent with the MSI status of this
tumor19.
This de novo chromatin state characterization provided a rich
reference resource (available at https://bioinformatics.ifom.eu/hepic/)
of regulatory elements (promoters and enhancers), elongating and
repressed genomic regions defined by multiple epigenetic features,
enabling a comprehensive interrogation of the colon cancer
epigenetic landscape.
Enhancerome definition of human CRC. We next sought to gain
further insights into the colon cancer enhancerome taking
advantage of this systematic reconstruction of the CRC epigen-
ome. To this end, we used the ChromHMM-defined enhancer
states, primarily enriched in H3K27ac and H3K4me1 (Fig. 2c), to
identify active distal enhancer regions in PDOs and normal colon
tissue. We found a total of 33,131 enhancers observed in at least
two PDOs and/or normal tissues and located >5 Kb from TSS
(Supplementary Data 4), covering 3% of the human genome.
Unsupervised clustering of the H3K27ac signals for the ~33 K
enhancers supported the discrete separation of the PDO enhan-
cerome from that of normal colon tissues (Fig. 3a). Genome-wide
analysis of H3K27ac signals in the ChromHMM-defined enhan-
cers, identified 7828 differentially enriched enhancers (gained or
lost) with >4-fold change (adjusted P-value < 0.01) in H3K27ac
between PDOs and normal tissues (Fig. 3b). Of these, 2419
enhancers (see Supplementary Fig. 4a for the genomic distribu-
tion) were specifically activated (gained) in PDOs and 5409 in
normal tissues.
To identify common epigenetic blueprints across the organoid
library, we looked at the concordance of tumor-enriched
enhancers in the PDOs. Among the gained enhancers, 20% were
concordant in 8 to 10 PDOs (n= 486 enhancers), while half of
them were shared by at least 5 patients (Fig. 3c and
Supplementary Fig. 4b, c), independently of their original
molecular and histological features (Fig. 1b and Supplementary
Table 1). An example of gained enhancers is shown for PHLDA1,
a gene upregulated in colon cancer and involved in tumor cell
proliferation and migration20. PHLDA1 displayed a conserved
epigenetic profile with peaks of H3K27 acetylation acquired in
enhancers across all PDOs compared to normal colon tissue
(Fig. 3d, vertical boxes). Conversely, the reduced expression of
Fig. 1 Establishment of a CRC PDO library that recapitulates the heterogeneity of the primary tumors. a Schematic depicting the generation of a patient-
derived organoid (PDO) library from primary CRC tissues and its subsequent morphological, transcriptomic, and epigenomic profiling. b Genetic and
molecular classification of primary tumors revealed the heterogeneity of the organoid library. CRC patients are classified based on the consensus molecular
subtypes2, the CRC intrinsic classifier3, and the CRCassigner14. MSI Microsatellite instable (blue), MSS Microsatellite stable (red), CMS Consensus
molecular subtypes, CRIS CRC intrinsic classifier. c Representative confocal images of 3D immunofluorescence whole-mount analysis on human CRC
PDOs. Different markers of colon cell types are shown: polarity and structure (F-Actin, first row), the epithelium (EpCAM, first row), proliferation (Ki67,
first row), absorptive cells (FABP1, second row), enteroendocrine cells (CHGA, second and third row), goblet cells (MUC2, third row), and top epithelial
crypt cells (KRT20, third row). The fourth row provides an enlargement of the boxed area in the third row. Scale bars, 100 µm. d PCA on normalised gene
counts from RNA-seq data distinguished normal colon mucosa, primary tumor, and PDOs. e, Venn diagram showing the number of concordant expressed
genes between tumors and PDOs. Mean log2 normalized gene counts between primary tumors and PDOs were well correlated (Pearson correlation). See
Supplementary Fig. 1b–d. f Hierarchical clustering analysis using differentially expressed genes (DEG, two-sided adjusted P-value≤ 0.01 by Wald test with
Benjamini–Hochberg false discovery rate correction) between tumor and normal colon tissues clustered PDOs together with parental tumors. Tissue
populations and patients are represented by color-coded bars above the heatmap. g PDOs are enriched in gene signatures of CRC clinical specimen15.
GSEA on the ranked list of genes from the comparison between PDOs and normal colon tissue with the normalized enrichment score (NES) and nominal
P-value using 1000 permutations reported.
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MUC4 during CRC progression is mirrored by the loss of
enhancer activity in all PDOs, as underlined by the absence of
active enhancers upstream of MUC4 (Fig. 3e). Overall, focusing
on ChromHMM-defined active enhancers, we characterized the
CRC enhancerome and identified the gained enhancers that are
shared across our heterogeneous PDOs.
YAP/TAZ are key regulators of the conserved CRC enhancer-
ome. Deciphering transcription factor occupancy at enhancer
regions is essential for understanding the transcriptional reg-
ulatory networks. Motif discovery identified the TEA domain
family members (TEAD) as enriched within the accessible regions














































































































































88,025 88,075 88,125 88,175 Kbchr2
FABP1 THNSL2SMYD1KRCC1
MSI - CMS3 - CRISA -
Goblet-like
MSS - CMS4 - CRISC -
Inflammatory
MSS - CMS1 - NA -
Inflammatory































MSS - CMS4 - CRISC -
Inflammatory
MSS - CMS1 - NA -
Inflammatory
MSS - CMS2 - CRISC -
Transient amplifying
OSBPL2 ADRM1 LAMA5 RPS21 RBBP8NL


















PDO 11 PDO 18 PDO 22 PDO 24

















NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-22544-y ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:2340 | https://doi.org/10.1038/s41467-021-22544-y | www.nature.com/naturecommunications 5
(Supplementary Data 5), suggesting a role for these factors and
their transcriptional coactivators YAP/TAZ, as putative regulators
of the conserved CRC enhancerome. This is further supported by
the enrichment of motifs for AP-1 factors (i.e., Jun and Fos family
members) in the same enhancers. Indeed, AP-1 has been recently
established as an intimate partner of YAP/TAZ/TEAD, co-
occupying disproportionally and pervasively cis-regulatory
regions also bound by YAP/TAZ and TEAD21.
Taking a different approach in identifying the main regulators
of the CRC enhancerome, we sought to determine which of the
genes annotated to gained enhancers were upregulated in the
majority of PDOs compared to normal tissues (P-adjusted < 0.05,
based on differential expression analysis of RNA-seq data). We
confirmed that the same genes were also upregulated in primary
tumors (Supplementary Fig. 4d). Active enhancers were assigned
to their putative target genes based on chromosome conformation
capture (capture Hi-C) data on human colon cancer22 or using
the nearest protein-coding gene overlapping a ChromHMM-
defined active promoter state (Supplementary Data 6). Notably,
functional enrichment analysis using the tumor-upregulated
enhancerome genes identified the Hippo signaling pathway as
the most significantly enriched pathway (Fig. 3f, g), confirming
the involvement of the Hippo pathway downstream effectors
YAP/TAZ in the activation of the CRC-specific active enhancers.
YAP/TAZ are found to be stably activated in CRC and other
types of cancer23. To validate the role of YAP/TAZ in the
regulation of the CRC enhancerome, we first examined their
expression. Both YAP and TAZ were transcriptionally upregu-
lated in PDOs and primary tumors compared to their normal
counterpart (Fig. 4a), with TAZ showing the largest difference in
gene expression levels compared to the normal tissue (log2FC >
7). Using RNA-seq data of COAD samples from the TCGA
dataset, we found that YAP/TAZ expression is also significantly
higher (P < 0.0001, Wilcoxon rank sum test) in tumor compared
to normal tissue samples (Supplementary Fig. 5a). Immunohis-
tochemistry analysis confirmed the presence of the active form of
the YAP and TAZ proteins in the nuclei of PDOs, as well as in
primary tumors compared to matched normal tissues (Fig. 4b), all
in all confirming the hyperactivation of these factors in CRC.
Using ChIP-seq, we generated a genomic map of TAZ
recruitment to the chromatin of PDOs. We identified 14,878
TAZ peaks distributed across ChromHMM-defined active
enhancers or promoters (Fig. 4c and Supplementary Data 7).
Representative examples of TAZ enrichment across the active
promoters of Hippo signaling canonical target genes are shown in
Fig. 4d and Supplementary Fig. 5b. The genomic distribution of
TAZ on target genes was also mirrored by the YAP ChIP-seq
profile (Supplementary Fig. 5b). Since YAP/TAZ do not bind
directly to DNA24, we searched for transcription factors binding
motifs encompassing the summit of YAP/TAZ peaks and we
found the TEAD family binding motif amongst the most enriched
(Fig. 4e), confirming the cooperative interaction of TEAD
transcription factors with YAP/TAZ in human CRC21.
To better characterize the genomic occupancy of YAP/TAZ, we
integrated ChIP-seq data for TAZ with all the CRC chromatin
states defined by ChromHMM. TAZ was enriched in active
regulatory states with more than 95% of TAZ peaks being present
in either promoters or enhancers (Fig. 4f), confirming the active
role of this transcriptional activator in CRC. Focusing on the
gained CRC-enhancerome, we assessed the overlap of TAZ peaks
with the total number of gained enhancers as well as those
conserved in at least 50 or 80% of PDOs. Notably, the percentage
of enhancer regions bound by TAZ increased with the level of
conservation between PDOs (Fig. 4g) up to 40% in the highly
conserved enhancers (n= 195, in 8 to 10 PDO lines, Supple-
mentary Data 8) indicating a role for TAZ in regulating a sizeable
fraction of the shared CRC enhancerome. In support, the TAZ
signal intensity at the conserved enhancers is significantly higher
(P= 0.028, Mann–Whitney U test) compared to that at non-
conserved gained enhancers (shared by <5 PDOs) (Supplemen-
tary Fig. 5c).
Interestingly, TAZ itself is regulated by a TAZ-bound intronic
enhancer (Fig. 4h, boxed area) that is shared by all PDOs. The
enrichment of TAZ at its own promoter and intronic enhancer
suggests a previously unnoticed feedback loop driving its
transcriptional activation. Another gene regulated by a TAZ-
bound enhancer is epiregulin (EREG), a ligand of the epidermal
growth factor (EGF) receptor, that is highly expressed in various
tumors25. EREG is a known target of the Hippo signaling pathway,
linked to intestinal stem cell maintenance and YAP function26.
The high expression of EREG in PDOs was regulated by two
separate enhancers located more than 200Kb downstream of the
gene and occupied by TAZ and the active histone marks
H3K4me1, H3K27ac, and H3K4me3 (Supplementary Fig. 5d).
Another gene of the TAZ-driven CRC enhancerome is the
Forkhead box Q1 (FOXQ1) member of the forkhead transcription
factor family, which is involved in CRC tumorigenicity and
growth27 with no previously reported role as a YAP/TAZ
downstream target gene. The high expression of FOXQ1 in PDOs
was controlled by a highly active enhancer bound by both TAZ
and YAP (Supplementary Fig. 5e). In situ hybridization in primary
healthy and tumor colon tissues confirmed that FOXQ1 gene
expression is restricted to the CRC sections that express YAP in
the nucleus (Supplementary Fig. 5f). Taken together, these results
revealed that the conserved cancer-cell intrinsic CRC-enhancer-
ome, shared by all PDOs and thus independent of patient-to-
patient tumor molecular diversity, is largely under the regulatory
control of YAP/TAZ, suggesting that these transcriptional
activators serve as central players in the epigenetic deregulation
of CRC. The role of YAP/TAZ as regulators of the conserved
enhancerome of human CRC nicely parallels functional evidence
in vivo, in mouse models, and in tumor organoids bearing YAP/
Fig. 2 Characterization of the human CRC epigenome using ChromHMM analysis. a Histone modifications localization in relation to the gene body as well
as regions surrounding ± 3 Kb of the transcription start (TSS) and end (TES) sites. Representative density plots of average intensity (top) and
corresponding heatmaps (bottom) display the relative distribution of H3K4me3 (red), H3K27ac (pink), H3K4me1 (yellow), H3K36me3 (green), and
H3K27me3 (gray) signals for all the genes present in the GENCODEv25 annotation. b Pearson correlation heatmap of ChIP-seq data for the complete set
of five histone modifications across all patient-derived organoids (PDOs). See Supplementary Fig. 2a. c Combinatorial pattern of histone marks in an 8-
state model using ChromHMM. The heatmap (Emission plot) displays the frequency of the histone modifications found in each state (Supplementary
Fig. 2b). d The probability of each ChromHMM-defined chromatin state overlapping ATAC-seq regions for TCGA colon adenocarcinoma samples is shown
across PDOs using a spider plot. e–f Representative tracks of ChromHMM states for the (e) FABP1 and (f) LAMA5 (Supplementary Fig. 3a) genomic loci in
all PDOs. The tracks denote regions identified as promoter (red), active enhancer (orange), weak enhancer (yellow), elongation (green), repressed (gray)
or quiescent (white) states (Fig. 2c). The expanded regions show H3K4me3, H3K27ac, H3K4me1, H3K36me3, and H3K27me3 profiles, along with RNA-
seq signal and ChromHMM states for PDOs of different molecular subtypes as indicated.
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TAZ knockout alleles, all in all indicating the centrality of YAP/
TAZ activation for CRC initiation and progression26,28,29.
YAP/TAZ are required for maintenance of tumor organoids.
We next aimed to validate the biological relevance of YAP/TAZ
for the survival of tumor cells. For this, we treated established
tumor (n= 6) and normal (n= 3) colon organoids derived from
nine independent CRC patients with verteporfin (VP), a YAP/
TAZ-specific inhibitor that blocks their interaction with the
transcription factor TEAD30,31. Following exposure to VP for 48
h, tumor organoids showed markedly suppressed growth and
extensive cell death compared to control (DMSO)-treated tumor
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organoids (Fig. 4i, left panel). Consistently, cell viability in tumor
organoids treated with VP was reduced up to 80% of control-
treated tumor organoids and was also significantly reduced (P=
0.012; one-sided Mann–Whitney U test exact P-value) compared
to VP-treated normal organoids (Fig. 4j and Supplementary
Fig. 5g). This is in agreement with the dispensability of YAP/TAZ
for normal physiology of the adult intestinal epithelium28. These
analyses strongly suggest that YAP/TAZ activation is not only a
hallmark of cancer initiation regulating the conserved enhan-
cerome landscape, but it is also essential for tumor maintenance.
Conserved CRC enhancerome is shared by diverse cancer types.
We next asked whether the YAP/TAZ-regulated enhancers
identified in CRC represent a conserved feature of epigenetic
deregulation in human cancer pathology. For this, we first
assessed the chromatin accessibility levels of the highly conserved
gained CRC-enhancers that are bound by YAP/TAZ (n= 195;
Fig. 4g and Supplementary Data 8) in 23 diverse cancer types
using ATAC-seq data obtained from TCGA17 (Fig. 5a). The 195
enhancer regions displayed a strong chromatin accessibility
profile across all COAD TCGA samples (Fig. 5a), validating their
regulatory role and underlining the CRC-specific nature of the
TAZ-regulated conserved enhancerome detected in the PDO
library. Notably, 46 out of the 195 active regulatory elements
(23%) were accessible in all cancer types (Fig. 5a, cluster in
magenta). We refer to these accessible and shared regulatory
elements as “ultra-conserved” providing a core of potential pan-
cancer enhancers that may be involved in the molecular
mechanisms at the basis of tumor biology and maintenance. To
validate the deregulation of these core enhancers, we examined
the H3K27ac enrichment across different primary tumors and
normal tissues. We found that the H3K27ac signal distribution at
the pan-cancer enhancers is significantly higher in primary
tumors (****P < 0.0001, Wilcoxon rank sum test; Fig. 5b; Sup-
plementary Data File 9), confirming the epigenetic rewiring of
these enhancer regions in diverse cancer types.
We next assessed the downstream effects of YAP/TAZ
regulation by identifying the target genes of the YAP/TAZ-
controlled enhancers. Focusing on those target genes that are
significantly more expressed in PDOs compared to normal tissues,
we confirmed that the majority of them are also upregulated in the
tumor samples of the COAD dataset (Supplementary Fig. 6a).
Among the genes annotated to the pan-cancer core enhancers, the
vast majority (80%) are also directly regulated by the binding of
TAZ on their promoters. Some of these genes are oncogenes (i.e.,
MYC) or known targets of YAP/TAZ (i.e., EREG, PHLDA1,
FJX1)28, whereas for other genes (i.e., UBE2H) there are no
previous reports of their role as YAP/TAZ target genes. The
intronic enhancer associated to TAZ (Fig. 5c, boxed area) was
among the 46 pan-cancer active regulatory regions bound by
YAP/TAZ. Indeed, PDOs, but not normal tissues, consistently
display H3K27ac enrichment in this region that coincides with
open chromatin or active H3K27ac profile in the vast majority of
tumors, suggesting the functional role of this transcriptional
activator in diverse human cancer types.
Overall, interrogation of chromatin accessibility data (TCGA)
confirms that the YAP/TAZ-regulated CRC enhancerome is
active in all the COAD samples. Moreover, extending the
significance of our findings to other cancer types, we reveal that
a pan-cancer core of enhancers displays an active and highly
conserved chromatin profile in several solid tumors, suggesting a
role for YAP/TAZ at the roots of deregulated gene expression of
the human cancer enhancerome.
Single-cell landscape of the pan-cancer core of enhancers. We
next sought to depict the cancer epigenetic deregulation at single-
cell resolution. To this end, we assessed the cellular distribution
and expression of the genes associated with the pan-cancer core of
enhancers using single-cell RNA-seq data of primary CRC
tissues32. We analyzed a total of 63,689 cells from tumor and
normal colon tissues of 23 patients comprising diverse tumoral
and normal cell populations of epithelial, stromal (endothelial
cells; fibroblasts), and immune cells (B and T lymphocytes; mye-
loid cells; mast cells) that offer a global cellular landscape of CRC
(Fig. 6a, Supplementary Fig. 6b). This dataset also represents the
heterogeneity of CRC with patients classified into different clinical
and molecular subtypes (Supplementary Fig. 6b). We then focused
on the cellular landscape of the genes annotated to the YAP/TAZ-
regulated pan-cancer enhancers (Fig. 5a, Supplementary Data 8)
that define a cancer regulatory blueprint. To better understand the
signal intensity and distribution of the gene signature, we created a
score of the cancer regulatory blueprint (CRB score) considering
both the expression level and co-expression of genes within a cell.
We found that the CRB score is highly enriched in the malignant
epithelial cells but largely absent from both normal epithelial and
other stromal/immune cells (Fig. 6b, c).
YAP/TAZ activation in tumor cells, amongst a diverse array of
downstream effects, promotes stem-like properties26,33. We thus
asked whether the epigenetically driven deregulation could relate
to stemness. To obtain a better resolution, we performed
subclustering analysis of normal and tumor epithelial cells
(Supplementary Fig. 6c) and found that malignant cells with an
active CRB do not necessarily display stem-like properties
(Fig. 6d–f, Supplementary Fig. 6d). This suggests that the
blueprint is a feature of cancer that relates to YAP/TAZ-driven
effects on tumoral transcriptional states that reach beyond the
acquisition of stemness.
Collectively, we show that the cancer regulatory blueprint is
enriched in the malignant cell populations despite the genetic and
transcriptional heterogeneity of primary tumors and is associated
Fig. 3 Differentially activated enhancers in human CRC. a Unsupervised clustering analysis and Pearson correlation heatmap of H3K27ac ChIP-seq data
for the 33,131 ChromHMM-defined active enhancers clearly distinguish patient-derived organoids (PDOs) from normal colon tissues. b Volcano plot of
differentially enriched enhancer regions between PDOs and normal colon mucosa. Dotted lines indicate thresholds for two-sided adjusted P-value < 0.01
and |log2 fold-change > 2 (Wald test with Benjamini–Hochberg false discovery rate correction). c Percentage of gained enhancers shared by different PDOs
(see Supplementary Fig. 4b, c). d–e Representative tracks of H3K27ac and ChromHMM profiles, illustrating examples of gained (d) and lost (e) enhancer
regions in PDOs compared to normal colon mucosa. Shaded boxes indicate the presence or absence of H3K27ac peaks. Interactions between gained
enhancers and promoter regions based on chromosome conformation capture (capture Hi-C) data on human colon cancer22 are shown below the graph.
f The Hippo signaling pathway is the most significantly enriched pathway related to the gained enhancer-associated genes that are upregulated in PDOs
compared to normal tissues. The size of the circles corresponds to the number of gained-enhancer associated genes present in the geneset of a particular
KEGG pathway (Gene Ratio). The dotted line indicates the threshold for significantly enriched pathways based on a two-sided Fisher’s exact test with a
false discovery rate (FDR) < 0.05. g Visualization of pathway network for tumor-upregulated genes annotated to gained enhancers based on functional
enrichment analysis. Pathway terms are represented by circles, the size of which is proportional to the number of genes. The circles are colored according
to the enrichment P-value based on a two-sided Fisher’s exact test.
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to an aberrant YAP/TAZ activation that is not related to stemness
per se.
Discussion
In our study, the epigenetic landscape of human CRC unveils the
existence of an aberrant pan-cancer core of enhancers regulated
by the transcriptional coactivators YAP/TAZ and active in more
than 20 types of human malignancies. The exploitation of pri-
mary tissue-derived tumor organoids, allowed us to dissect cancer
cell-intrinsic epigenetic alterations devoid of the influence of
stromal cells, and provided sufficient material to perform a sys-
tematic de novo discovery of biologically informative chromatin
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histone marks we identified 8 different epigenetic states (Fig. 2c),
revealing the genome-wide location of promoter and enhancer
regions, as well as elongating and repressed genomic regions. This
data generates an extensive functional annotation of the human
genome in CRC allowing the interrogation of diverse modes of
epigenetic regulation. These are complemented by matched
transcriptomic profiles providing a comprehensive view of cor-
related activity patterns in human CRC and an essential resource
for exploring not only the private epigenetic programs that drive
patient heterogeneity but also the common epigenetic blueprints.
To facilitate the public use of these omics resources we have
created HePIC, a web application tool (publicly available at
https://bioinformatics.ifom.eu/hepic/) that allows the interactive
visualization of both epigenomic (ChIP-seq on histone marks and
ChromHMM tracks) and transcriptomic (RNA-seq) data for all
the PDOs analyzed in this study.
Epigenomic events and post-transcriptional processes34 are
involved in intestinal homeostasis and colon cancer. Among the
epigenetically controlled genomic elements, enhancers are
attracting considerable attention due to their fundamental role in
tumor development, progression, and metastasis6,7. We used
chromatin states to provide a more robust annotation of the
different classes of enhancers compared to predictions based on
ATAC-seq data17 or individual histone marks35,36. As a result, we
were able to discriminate active enhancers from other genomic
elements within chromatin accessible regions, as exemplified by
the epigenetic profiling of the TAZ gene locus (Fig. 5c), where
multiple open chromatin regions across diverse tumor types
correspond to only a handful of active enhancers. These findings
are in line with reports by us and others37 that less than a third of
all ATAC-seq identified regions intersect with ChromHMM-
defined enhancers, with merely 17% of open chromatin regions
for COAD qualifying as active enhancers.
Human CRCs are characterized by ostensibly endless combi-
nations of oncogenic lesions resulting in a high degree of intra-
tumoral and intertumoral genetic heterogeneity38. Is the
epigenetic level similarly complex or, rather, does it represent a
much-simplified layer of integration of genetic and micro-
environmental inputs into a restricted, shared set of transcrip-
tional states? Based on ChromHMM-defined chromatin states, we
found two main groups of enhancers that are differentially active
in PDOs compared to normal mucosa. While half of these
enhancers displayed low levels of conservation across PDOs, the
remaining half was conserved in at least 50% of the tumor
organoids (Fig. 3c), including those displaying microsatellite
instability (Fig. 1b). This comes in striking contrast with the
reported recurrence of mutated genes in CRC; with the exception
of few driver genes the vast majority of the recurrently mutated
genes are shared by <10% of tumors38. Thus, our findings indi-
cate that despite the profound genetic heterogeneity, CRC is
characterized by a common aberrant enhancerome.
To provide an in-depth characterization of the shared CRC
enhancerome, we sought to understand which transcription fac-
tors orchestrate the activation of these cis-regulatory elements.
Although multiple factors may facilitate cell deregulation in CRC,
our motif discovery and functional enrichment analyses high-
lighted the AP1 and TEAD families along with the Hippo path-
way, pinpointing the YAP/TAZ transcriptional coactivators as
major regulators of the human CRC enhancerome. In line with
their pervasive activation in human epithelial tumors23, we con-
firmed the transcriptional upregulation and nuclear translocation
of YAP/TAZ, and further unveiled the YAP/TAZ chromatin
recruitment at distal enhancers in human CRC. In addition, we
found an enrichment of TEAD and AP1 motifs at YAP/TAZ-
bound genomic elements, supporting the involvement of these
TFs as YAP/TAZ partners also in this type of cancer, as suggested
by previous studies21,39.
Strikingly, YAP/TAZ were most enriched in the highly con-
served gained enhancers (Fig. 4g), highlighting these transcription
factors as driving forces of the shared CRC deregulated enhan-
cerome. The relevance of this epigenetic signature was extended
to diverse malignancies of epithelial cells suggesting a previously
undescribed universal role for YAP/TAZ as master regulators of
tumor-associated epigenetic shifts. In light of the recently
reported YAP/TAZ-dependent transcriptional addiction in
cancer10, we speculate that the core of 46 pan-cancer gained
enhancers identified in our study could be at the root of the
cancer transcriptional addiction, representing a unique epigenetic
“fil rouge”.
Still, there are unaddressed questions regarding the regulation
of YAP/TAZ. Interestingly, we found a tumor-specific epigenetic
mechanism of TAZ auto-regulation: a positive feedback loop
between an intronic YAP/TAZ-bound active enhancer and TAZ
promoter itself, shared by all CRC PDOs. This intronic enhancer
was also observed in the TCGA panel of 23 tumor types, sug-
gesting that the TAZ self-regulation is relevant to a wide range of
cancers (Fig. 5c). This transcriptional feedback mechanism
combined with the inhibition and persistent activation of the
Hippo and Wnt pathways, respectively40, may provide a constant
fuel of YAP/TAZ for uncontrolled proliferation of tumor cells,
sustaining the YAP/TAZ-dependent transcriptional addiction in
cancer10. YAP/TAZ activation can be influenced by heterogenous
cancer-cell intrinsic features (i.e., underlying genetic lesions) and
mechanical cues, and is interconnected with mitogenic signals
Fig. 4 YAP/TAZ regulates the conserved human CRC enhancerome. a YAP and TAZ are transcriptionally upregulated in primary tumors (n= 10) and
patient-derived organoids (PDOs n= 10) compared to normal colon tissues (n= 9). Violin plots of log2 normalized gene counts. **P < 0.01, ***P < 0.001,
two-sided Wilcoxon rank sum exact test. b Representative immunohistochemistry images with insets showing YAP/TAZ nuclear localization in tumor
tissues (middle) and PDOs (bottom) compared to normal mucosa (top). Scale bars, 50 µm, magnification ×40. c Relative distribution of TAZ peaks around
ChromHMM-defined active enhancers (n= 33,131, yellow) and promoters (red). d Genomic overview of YAP/TAZ canonical targets showing H3K4me3,
H3K27ac, H3K4me1, TAZ profiles, and ChromHMM states (see Supplementary Fig. 5b and Fig. 2c, e for details on ChromHMM tracks). e TEAD binding
motif enrichment around the summit of TAZ peaks. f Distribution of TAZ peaks across ChromHMM-defined functional elements. g TAZ enrichment in
human CRC gained enhancers (G.E.) increases with the level of enhancer conservation across PDOs. The bar plots show the percentage of enhancers in
each G.E. subset that overlap a TAZ peak or the percentage (mean ± s.d.) of TAZ-bound regions in 1000 random sets generated for each G.E. subsets: (i)
all G.E., (ii) G.E. conserved in >5 patients, and (iii) G.E. conserved in >8 patients (see “Methods”). ***P < 0.001, one-sided empirical P-value. h TAZ genomic
overview showing H3K4me3, H3K27ac, H3K4me1, and TAZ profiles, RNA-seq signals, ChromHMM states, and capture Hi-C promoter-enhancer
interactions. i YAP/TAZ-inhibition affects patient-derived tumor organoid growth. Representative images of fully formed normal (left) and tumor (right)
organoids cultured for 48 h following treatment with 1 μM of verteporfin (VP; top) or DMSO (bottom). Scale bar: 100 μm, magnification ×10. j VP
treatment significantly reduces cell viability in tumor compared to normal PDOs. Viability was assessed by flow cytometry 48 h after exposure and
normalized to DMSO (mean ± s.d., n: Normal= 3 and Tumor= 6 independent CRC patients; see Supplementary Fig. 5g). *P= 0.012, one-sided
Mann–Whitney U exact test.
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(i.e., MYC) and WNT/β-catenin signaling28,33,41. Nevertheless,
the YAP/TAZ-mediated addiction concurs with our observations
at the single-cell level that the epigenetic deregulation is shared by
malignant cell populations of diverse CRC subtypes (Fig. 6d and
Supplementary Fig. 6d). In support, our experimental studies
demonstrate that inhibition of YAP/TAZ in fully established
human CRC organoids causes growth defects and extensive cell
death. Overall, these findings suggest a key role for YAP/TAZ in
sustaining a core gene-regulatory network intrinsic to CRC and
possibly other malignancies, that is essential for the maintenance
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Deeper understanding of the mechanisms by which YAP/TAZ
exert their nuclear functions can link the inhibition of these coac-
tivators to an arsenal of potent epigenetic agents. For instance, YAP/
TAZ-mediated transcriptional addiction is achieved through inter-
action with the bromodomain and extraterminal domain (BET)
coactivator BRD4, demonstrating the rational use of BET inhibitors
in impairing the expression of YAP/TAZ-regulated genes and YAP/
TAZ-induced oncogenic functions and drug resistance10. A different
approach to control YAP/TAZ activity could arise from the epige-
netic modulation of TAZ gene expression. The dispensability of
YAP/TAZ for normal tissue homeostasis26,28, also confirmed by us,
provides a further argument in favor of exploiting YAP/TAZ as
master regulators of a cancer regulatory blueprint to discover
potential targets for epigenetic-based therapeutic approaches.
Fig. 5 Conserved human CRC enhancer regions are accessible across diverse cancer types. a Chromatin accessibility profiles of the 195 conserved
gained enhancers in 23 diverse primary human cancer types reveal a signature of 46 pan-CRC enhancers with active chromatin profiles across cancer
types (cluster in purple). The heatmap shows hierarchical clustering of log2 normalized insertion counts of ATAC-seq data derived from TCGA (Corces
et al.17). Colon adenocarcinoma samples are the first cancer type reported on the left of the heatmap. The color-coded bar above the heatmap represents
the different cancer types: ACC adrenocortical carcinoma, BLCA bladder urothelial carcinoma, BRCA breast invasive carcinoma, CESC cervical squamous
cell carcinoma, and endocervical adenocarcinoma, CHOL cholangiocarcinoma, COAD colon adenocarcinoma, ESCA esophageal carcinoma, GBM
glioblastoma multiforme, HNSC head and neck squamous cell carcinoma, KIRC kidney renal clear cell carcinoma, KIRP kidney renal papillary cell carcinoma,
LGG brain lower grade glioma, LIHC liver hepatocellular carcinoma, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, MESO
mesothelioma, PCPG pheochromocytoma and paraganglioma, PRAD prostate adenocarcinoma, SKCM skin cutaneous melanoma, STAD stomach
adenocarcinoma, TGCT testicular germ cell tumors, THCA thyroid carcinoma, UCEC uterine corpus endometrial carcinoma. b Differences in the H3K27ac
intensities of the pan-cancer enhancers in primary tumors (n= 28) relative to normal tissues (n= 15) from public ChIP-seq data. Boxplots describe the
median (middle line) and interquartile range (box denoting first and third percentile) with whiskers denoting the minimum and maximum within the 1.5×
interquartile range and outlying points beyond the whiskers plotted individually. ****P < 0.0001, two-sided Wilcoxon rank sum exact test. c Genomic
overview of the TAZ locus in representative normal tissue and patient-derived organoid (PDO) samples, and in TCGA cancer types. Upper panel: H3K27ac
profiles, ChromHMM states and RNA-seq signals in normal tissue; H3K27ac and TAZ profiles, ChromHMM states, and RNA-seq signals in PDO; and CRC
capture Hi-C data. Bottom panel: ATAC-seq profiles for 23 TCGA cancer types. The shaded box indicates a CRC-conserved and YAP/TAZ-bound








































































Fig. 6 Distribution of cancer epigenetic deregulation at single-cell level. a t-distributed stochastic neighbor embedding (t-SNE) visualization depicting the
major cell types identified in scRNA-seq data of primary tumor and normal tissues from 23 CRC patients. b t-SNE visualization of the CRB scores across all
cell populations. c Malignant cells display significantly higher CRB scores. Distribution of the CRB score in the malignant (gray; n= 17,469) and non-
malignant epithelial clusters (green; n= 1070), and in all other major cell populations (B cells n= 9146; Mast cells n= 187; Myeloid cells n= 6769; Stromal
cells n= 5933; T cells n= 23,115). Boxplots describe the median (middle line) and interquartile range (box denoting first and third percentile) with whiskers
denoting the minimum and maximum within the 1.5× interquartile range. ****P < 0.0001, two-sided Mann–Whitney U test. d–e t-SNE representation of the
CRB (d) and stemness (e) scores across 18,539 epithelial cells. Contour lines denote normal epithelial cells. f The cancer regulatory blueprint does not
relate to stemness. t-SNE representation of the difference between the CRB and stemness score across all epithelial cells. Cells depicted in gray display
similar levels of the two scores, whereas cells in purple and green display mutually exclusive high levels of CRB or stemness, respectively. Contour lines
denote normal epithelial cells.
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Methods
Human specimens. Primary CRC tissues were obtained from San Gerardo Hos-
pital (Department of Surgery), Monza and UO Chirurgia Epatobiliopancreatica e
Digestiva Ospedale San Paolo, Milan following ethical approval from their Insti-
tutional Review Boards. Written informed consent was obtained from all patients
for the usage of their samples for research purposes, including the creation of
PDOs. Clinical details on patients are provided in Supplementary Table 1. Samples
were confirmed to be tumor or normal based on pathologist assessment and were
obtained prior to treatment. MSI-MSS status was determined according to standard
experimental procedures42.
Isolation of human primary tissues. Primary colonic normal and tumoral tissues
were processed as described below43. Surgically resected specimens were reduced to
a size of 3–5 mm, extensively washed with cold PBS and gentamicin (20 μg/ml) and
incubated with PBS-EDTA (2.5 mM) rocking on a wheel for 1 h at 4 °C. After PBS-
EDTA treatment, tissue samples were washed with cold PBS—1% FBS to release
normal crypts and tumoral counterpart. Cells suspension were collected by cen-
trifuging at 400 × g for 5 min at 4 °C and used for transcriptomic and epigenomic
analyses.
CRC patient-derived organoid libraries. CRC and normal colon PDOs were
established and maintained as described below43. Tumor and normal cell sus-
pensions isolated from surgical resections were embedded in drops of Matrigel®
Growth Factor Reduced Basement Membrane Matrix, Phenol Red-Free (Corning)
to establish CR/CRC PDOs libraries. Droplets of matrigel containing tumor/nor-
mal cells suspension or established organoids were maintained in 24-well plates
overlaid by 500 µl of the organoid culture medium (Advanced DMEM/F12
(Life Technologies) supplemented with penicillin/streptomycin (Euroclone),
10 mM HEPES (Life Technologies), 2 mM GlutaMAX (Life Technologies), 1X B27
(Life Technologies), 1X N2 (Life Technologies), 1 mM N-Acetyl Cysteine (Sigma-
Aldrich), 10 mM Nicotinamide (Sigma-Aldrich), 50 ng/ml human EGF (Pepro-
tech), 100 ng/ml human Noggin (Peprotech), 10 nM human Gastrin (Sigma),
500 nM A83-01 (Tocris), 10 μM SB202190 (Sigma). The normal colon PDOs were
cultured also in the presence of 50% Wnt3a-conditioned media (stably cell line
produced in-house) and 1 µg/ml human RSPO1 (Peprotech, 120-38). The orga-
noids were split once per week by mechanical disruption or enzymatic digestion
using TrypLE™ Express Enzyme (Thermo Fisher, 12605010) and regularly checked
for mycoplasma contamination. For the VP experiment, the normal/tumoral PDO
lines were treated with 1μM VERTEPORFIN (VP - Sigma-Aldrich, SML0534) or
its vehicle dimethyl sulfoxide (DMSO - Sigma-Aldrich, D2650) as control for 48 h.
Organoid immunofluorescence and microscopy. For whole-mount staining44,
isolated organoids embedded in Matrigel in µ-Plate Angiogenesis 96 Well (Ibidi),
were fixed in 4% paraformaldehyde in PBS for 1 h, at 4 °C. After fixation, the
autofluorescence was quenched with 50 mM NH4Cl for 30 min and the organoids
were permeabilized with 0,5% Triton X-100 (Sigma-Aldrich) for 1 h and blocked
with 10% Donkey Serum or Normal Goat Serum (Sigma-Aldrich) in PBS with 0.2%
Triton X-100 overnight, at 4 °C in mild shaking. Primary and secondary antibodies
were diluted in 5% of serum and incubated for ~35 and ~12 h, respectively, at 4 °C
in mild shaking (Supplementary Table 2). Cell nuclei were stained with 20 μg/ml
Hoechst 33342 in PBS with 0.2% Triton X-100 for 2 h and the organoids were
stored in PBS with 0.02% NaN2 until the acquisition. Fluorescence images were
captured with confocal laser-scanning SP5 microscope (Leica Microsystems)
equipped with eight laser lines and four PMT detectors, using 10× (NA 0.3) or 20×
(NA 0.7) dry objectives (TCS SP5; Leica), 5 or 10 µm z-step interval and 1024 ×
1024 or 2048 × 2048 image format. For each acquired confocal z-stack field,
maximum intensity projections (MIP) were generated using ImageJ software
(National Institutes of Health). For YAP/TAZ-inhibition experiment, normal and
tumoral PDOs were seeded in 96-well plate at the same confluence and followed in
live imaging for 48 h at Leica Thunder Imaging System. Each brightfield (BF)
image was captured every 16 h using 20 μm Z-steps and was processed for tiling
and extended depth of field (EDF). Further image analysis was performed using Fiji
software (v2.1.0/1.53c) (National Institutes of Health).
Immunohistochemistry and in situ hybridization. Immunohistochemical stain-
ing of human CRC primary tissues and PDOs was performed on formalin-fixed,
paraffin-embedded, or on fresh OCT-embedded tissue and PDO sections (Fig. 4b
and Supplementary Fig. 5f). For immunohistochemistry, frozen samples were
cryostat sectioned, fixed in 100% cold acetone for 2 min, blocked with 2% FBS
serum in PBS for 60 min, and incubated overnight with primary antibodies
(WWTR1/TAZ 1:20 Sigma-Aldrich, HPA007415; YAP 1:100, Santa Cruz Bio-
technology – Sc-101199). The antibodies were detected using a polymer detection
kit (GAM/R-HRP, Microtech) followed by a diaminobenzidine chromogen reac-
tion (Peroxidase substrate kit, DAB, SK-4100; Vector Lab). All sections were
counterstained with Harris’s Hematoxylin and visualized using a bright-field
microscope. For in situ hybridization, tissue sections (formalin fixed, paraffin
embedded) were processed for RNA in situ detection using the RNAscope Duplex
Detection Kit (Chromogenic) according to the manufacturer’s instructions
(Advanced Cell Diagnostics). RNAscope probe was FOXQ1 (NM_033260.3, region
694 - 2197), which was detected using the HRP-based Green detection reagent.
Flow cytometry. Normal and tumoral PDOs treated with VP or DMSO were
collected and dissociated to single-cell level using TryPLE express solution, for 5
min at 37 °C. Cells were stained with Fixable Viability Stain 780 (FVS780 - BD
HORIZONTM, 565388) according to manufacturer’s instructions and samples were
acquired at FACSCanto II (BD), following the manufacturer’s instructions (Sup-
plementary Fig. 5h for gating strategy).
RNA isolation and bulk RNA-seq library construction. For RNA-seq analysis,
cell suspensions from CRC PDOs, primary normal, and tumor tissues were lysed in
TRIzol reagent (Thermo Fisher) and processed for total RNA extraction with
PureLink™ RNA Mini Kit (Thermo Fisher), according to manufacturer’s instruc-
tions. PDOs samples were collected at early (<5 splits) and late passages (>5 splits).
The RNA quality was assessed by the RNA Integrity Number (RIN) value with
RNA6000 assay (Agilent). Only samples with RIN > 7.0 were used in this study.
RNA-seq libraries were constructed according to the TruSeq mRNA Stranded
preparation kit (Illumina, San Diego, USA) and sequenced at HiSeq2500.
Chromatin immunoprecipitation (ChIP) assay. For ChIP experiments, matrigel
droplet containing ~0.3 × 106 organoid cells/well was dissolved using Cell Recovery
Solution (Matrisperse Cell Recovery Solution - Sacco-L004419 CPB40253), fol-
lowing the indicated procedure. PBS-washed organoids pellet was fixed as a whole
in Formaldehyde (F8775 SIGMA) PBS-solution (final 1%), for 10 min rocking at
room temperature and quenched with 0.125 M Glycine for 5 min. PBS-washed
organoid pellets were lysed with 500 μl of 1× sonication lysis buffer (10 mM Tris
pH 8.0, 0.25% SDS, 2 mM EDTA, plus protease inhibitors) and incubated for at
least 10 min at 4 °C. Lysed chromatin was sheared at 200–500 bp fragments using
Covaris® M220 focused-ultrasonicator (settings: duty factor 20%, peak incidence
power 75 Watt, cycles per burst 200, 8–15 min). For organoids and primary tissues
~500 ng and ~1000 ng respectively of the sonicated chromatin was incubated with
0.5/1 μg of histone mark antibodies (H3K27Ac abcam 4729; H3K4me3 Millipore
07-473; H3K4Me1 DIAGENODE C15410194; H3K36me3 DIAGENODE
C15410192; H3K27me3 07449 Millipore), overnight at 4 °C. Immunocomplexes
were recovered the following day with blocked 10 μl Protein G-Dynabeads
(Thermo Fisher) for 2 h at 4 °C and washed twice with RIPA-low salt (10 mM Tris-
HCl pH 8.0, 140 mM NaCl, 1 mM EDTA pH 8.0, 0.1% SDS and 0.1% Na-Deox-
ycholate, 1% Triton x-100), twice with RIPA-high salt (10 mM Tris-HCl pH 8.0,
1 mM EDTA pH 8.0, 500 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.1% DOC),
twice with RIPA-LiCl (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0, 250 mM
LiCl, 0.5% NP-40, 0.5% DOC), once with 10 mM Tris pH 8.0 and once with 1X TE,
followed by reverse crosslinking overnight. The washed immunocomplexes were
incubated with ChIP elution buffer (10 mM Tris-HCl pH 8.0, 5 mM EDTA pH 8.0,
300 mM NaCl, 0.4% SDS) supplemented with 0.8 mg/ml Proteinase K for 1 h at
55 °C and overnight at 65 °C, for reverse crosslinking. The immunoprecipitated
DNA was then purified by Qiagen MinElute kit (Qiagen) and eluted in 22 μl EB
buffer. ChIPmentation on YAP/TAZ45 was carried out, with the following mod-
ifications. Briefly, crosslinked organoids were lysed in buffer I (50 mM HEPES, pH
7.5, 10 mM NaCl, 1 mM EDTA, 10% Glycerol, 0.5% NP-40, 0.25% Triton X-100,
plus protease inhibitors) in ice. Organoids were recovered and lysed in buffer II
(10 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, plus
protease inhibitors) at room temperature. Organoids pellet was sonicated in lysis
buffer III (10 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA,
0.1% Na-deoxyxholate, 0.5% N-lauroysarcosine, plus protease inhibitors) using
Covaris® M220 focused-ultrasonicator. Sonicated chromatin was incubated with
anti-WWTR1 (Sigma Aldrich, HPA007415), anti-YAP1 (abcam 52771), or anti-
rabbit IgG (SinoBiological CR1) overnight at 4 °C on the wheel. Antibody/antigen
complexes were recovered with blocked Protein G-Dynabeads (Life Tecnologies)
and washed with low salt wash buffer ((20 mM Tris-HCl pH 8.0, 150 mM NaCl,
0.1% SDS, 1% Triton X-100 and 2 mM EDTA), high salt buffer (20 mM Tris-HCl
pH 8.0, 2 mM EDTA, 500 mM NaCl, 0.1% SDS, and 1% TritonX) and with 10 mM
Tris pH 8.0. Washed immunocomplexes were resuspended in tagmentation reac-
tion (Nextera DNA Sample Prep Kit (Illumina)), as described in Schimdl et al.45.
Beads were washed with low-salt buffer, 1X TE and incubated with ChIP elution
buffer (10 mM Tris pH 8.0; 5 mM EDTA; 300 mM NaCl; 0.4% SDS) plus 0.8 mg/ml
Proteinase K (NEB) for 1 h at 55 °C and 8 h at 65 °C, to revert formaldehyde cross-
linking. The immunoprecipitated and input DNA were then purified by Qiagen
MinElute kit (Qiagen) and eluted in 22 μl EB buffer.
ChIP-seq library preparation. ChIP-seq libraries were constructed with TruSeq
ChIP Library Preparation Kit (Illumina), according to the manufacturer’s
instructions and sequenced on Illumina HiSeq2500 platform. Library preparation
for ChIPmentation was performed using Nextera primers45 (Supplementary
Table 3) and enriched libraries were purified using 1.8 V of SPRI AMPure XP beads
and sequenced with Illumina HiSeq2500.
RNA-seq QC and data analyses. Quality control of the reads was performed with
FastQC (v0.11.7) and MultiQC (v1.5) (http://www.bioinformatics.babraham.ac.uk/
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projects/). The reads were trimmed using BBDuk – BBMap v38.16 (https://jgi.doe.
gov/data-and-tools/bbtools/bb-tools-user-guide/bbmap-guide/) (command line
parameters: ktrim= r k= 23 mink= 11 hdist= 1 tpe tbo qin= 33) and aligned to
the human hg38 reference (GENCODE Release 25 basic gene annotation) using
STAR (v2.5.3a)46 (command line parameters: --utFilterMismatchNmax 9 --out-
FilterMultimapNmax 20 -- alignSJoverhangMin 8 --alignSJDBoverhangMin 1).
Quantification was performed using featureCounts47 – Subread v1.6.2 with default
parameters. RNA-seq and ChIP-seq primary analyses were executed by a custom
pipeline managed by Nextflow (v20.04.1.5335)48.
The raw count matrix containing all the samples was created using a custom
bash script. Mitochondrial genes were removed from downstream analyses.
Normalization and differential analysis were carried out using DESeq2 package
(v1.22.2)49 and R (v3.5.1)50. Sample variance for each gene was calculated using the
rowVars function of R across all samples. PCA was performed using the R function
prcomp considering the 500 most variable transcripts with parameters center=
TRUE, scale= TRUE. The 500 most variable genes were manually inspected and
immune/stroma infiltrate-related genes were removed (Supplementary Data 2).
Genes were considered differentially expressed with a P adjusted ≤ 0.01 upon
correction for multiple testing using the Benjamini–Hochberg method in DESeq. A
single organoid for each patient was chosen for downstream differential expression
analyses in order to maintain an even sample size across the three experimental
groups. Heatmap and hierarchical clustering were performed using Z-score
normalized counts of DEG and the pheatmap function with default parameters
(clustering_distance_cols= euclidean, clustering_method= complete). GSEA was
performed using the GSEApy (v0.9.9)51 package utilising the pre-ranked module
with default parameters (permutation_num= 1000). For the visualization of RNA-
seq tracks, normalized coverage tracks were generated using the bamCoverage
(command line --normalizeTo1x 3049315783 --minMappingQuality 10) function
of deepTools (v2.5.7)52. Separate tracks for forward and reverse transcripts were
generated for each independent sample.
Tumor primary tissue classification. The classification of CRC primary tissues
was based on the Consensus Molecular Subtype2, the CRC intrinsic subtypes3, and
the CRCassigner14 classification systems. The classification was performed using
the CMScaller53 R package (https://github.com/peterawe/CMScaller) with default
parameters (false discovery rate (FDR)= 0.5, seed= 1).
ChIP-seq data processing. Quality control of the reads was performed with
FastQC v0.11.7 and MultiQC v1.5. Reads were aligned to the human hg38 refer-
ence (GENCODE Release 25 basic gene annotation) using Bowtie (v1.2.2)54
(command line parameters: -m 1 --best --strata -v 3), sorted using SAMtools
(v1.8)55 and directly converted into binary files (BAM). PCR duplicated reads were
marked and removed using SAMtools. The peaks were called with MACS2
(v2.1.0)56 (command line parameters: --nomodel --extsize 200 -B -q 0.01 for sharp
histone modifications H3K4me3 and H3K27Ac, and adding --broad for broad
histone modifications H3K4me1, H3K36me3, and H3K27me3) using matched
input DNA as a control. Peaks overlapping ENCODE blacklisted regions hg38 (i.e.,
regions in the human genome with signal artefacts in next-generation sequencing
experiments, (https://www.encodeproject.org/annotations/ENCSR636HFF/) were
removed. Peaks found in un-placed and un-localized scaffolds were removed. For
the visualization of ChIP-seq tracks, Bedgraph tracks were generated using MACS2
bdgcmp function, and converted into bigwig using UCSC bedClip and bed-
GraphToBigWig functions. pyGenomicTrack57 was used for the visualization of the
tracks.
Filtered and sorted BAM files were used to generate normalized coverage tracks
using the bamCoverage function from deepTools suite v2.5.7 (--normalizeTo1x
3049315783 --extendReads 200 --binSize 1). The average signal profile and the
heatmap plot along the genebody were calculated using computeMatrix scale-
regions with default parameters (--regionBodyLength 6000 --upstream 3000
--downstream 3000) and GENCODE Release 25 basic gene annotation.
Correlation analysis of histone marks. To obtain the correlation heatmap of all
the histone modifications for the ten PDOs, a consensus peakset was generated
using DiffBind (v2.6.6)58 by merging together only peaks detected in at least two
tracks. Then, a count matrix of 180,250 peaks × 48 samples was created by counting
the number of reads per peak for each sample using the dba.count with default
parameters. The correlation heatmap and PCA plot were produced using dba.
plotHeatmap (distMethod= “pearson”) and dba.plotPCA respectively, with default
parameters.
Analyses of publicly available ChIP-seq datasets. Publicly available ChIP-seq
datasets for normal and tumor colon tissues (GSE77737), and colon cancer cell
lines HCT116 and Caco2 (ENCODE) (Supplementary Data File 3) were reanalyzed
and processed using the same pipeline described above. Publicly available datasets
for H3K27ac ChIP-seq used in Fig. 5b (Supplementary Data File 9) can be found
under accession codes GSE51776 (gastric cancer), GSE114737 (breast and endo-
metrial cancer), GSE74230 (osteosarcoma), GSE101065 and GSE142924 (uterus),
GSE16256 and GSE96504 (liver), GSE16256, GSE101019, and GSE95966 (adrenal
gland), GSE101258, GSE96258, GSE95981, and GSE142995 (thyroid gland),
GSE16256, GSE101269, GSE101231, GSE142968, GSE96212 (pancreas).
De novo chromatin state characterization. De novo chromatin state character-
ization of all PDOs was performed using a multivariate Hidden Markov Model
approach implemented in ChromHMM (v1.12)16 considering five histone mod-
ifications (H3K4me3, H3K27ac, H3K4me1, H3K36me3, and H3K27me3) across
ten PDOs and including additional public available ChIP-seq data (Supplementary
Data 3), using default parameters. The read counts for all the considered samples
were computed in non-overlapping 200-bp bins across the entire genome. The
presence or absence of each histone mark is determined within each interval based
on the observed reads counts relative to a Poisson background distribution,
Binarization was performed comparing ChIP-seq read count to corresponding
input DNA as a control to reduce the technical noise. Several models were trained
in parallel using 8, 10, and 12 states. The 8-state model was chosen for downstream
analysis since it captured the key interaction between histone marks with minimal
redundancy. Figure 2c reports the histone marks emission probability heatmap
which represents the frequency with which different histone modifications are co-
present in the same genomic region. The annotation names attributed to the states
were defined based on the Roadmap Epigenomics Consortium nomenclature59.
Briefly, two states were annotated as promoter states (“Flanking Active TSS -
FlnkActTSS” and “Active TSS - ActTSS”) based on the presence of H3K4me3, or
the enrichment of both H3K4me3 and H3K27ac, respectively. The two states with
strong enrichment of H3K4me1 and H3K27ac and absence of H3K4me3 were
defined as “Flanking Active Enhancers - FlnkActEnh” and “Active Enhancers -
ActEnh”. The state characterized by the presence of H3K4me1 alone was defined as
“Weak Enhancers - WkEnh”. The “Elongation – Elong” and “Repression - Repr”
states were characterized by the presence of H3K36me3 and H3K27me3, respec-
tively. “Quiescence” state marks regions without any significant enrichment of
histone marks.
Overlap of ChromHMM states and COAD ATAC-seq data. We estimated the
probability of detecting previously reported open chromatin regions for colon
cancer within each chromatin state. To this end, ATAC-seq data for COAD was
downloaded from the TCGA site (https://gdc.cancer.gov/about-data/publications/
ATACseq-AWG/)17. The number of ATAC-seq peaks inside each ChromHMM
state was defined by overlapping the regions of each ChromHMM state with the
ATAC-seq peak summits. Since each ATAC-seq peak was reduced to the summit
of the peak, the length of each ATAC-seq peak corresponded to 1 bp. Then, a
conditional probability was calculated to estimate the probability of identifying
open chromatin regions in each chromatin state across the ten PDOs. The prob-
ability p(A|B) is the probability that event A will occur given the knowledge that
event B has already occurred. The conditional probability of A given B is defined as
the quotient of the probability of the joint event A and B (both events A and B
occur together) and the probability of B (1).
pðAjBÞ ¼ pðA\ BÞ
pðBÞ ð1Þ
For “i”= 1..n where n is the number of chromatin states, p(A), p(B) and p(A∩ B)
were defined as follows:
p(A)= total length of ATAC-seq peaks/total length of the genome
p(B) = total length of ChromHMMi state/total length of the genome
pðA\ BÞ = total length of ATAC-seq peaks overlapping ChromHMMi state/
total length of the genome
With p(A|B) defined as the probability of finding ATAC-seq peaks in each
ChromHMM state:
p(A|B)= total length of ATAC-seq peaks overlapping ChromHMMi state/total
length of ChromHMMi state.
Identification of active enhancers. To identify tumor-specific active enhancers,
all the “Active Enhancer” and “Flanking Active Enhancers” regions from the ten
PDOs and the five normal colon tissue ChromHMM states were selected. These
two states are defined by the co-presence of high level of H3K27Ac and
H3K4me1 signals. The pool of active enhancer regions was filtered excluding all
regions with <200 bp length and within a window of 5 Kb around the TSS (based
on known genes within GENCODE Release 25 basic gene annotation). Then, a
consensus peakset was built using DiffBind, as described for correlation analyses of
histone marks. The number of H3K27ac reads in the consensus peakset was
counted generating a count matrix of 33,131 regions × 15 samples. Differential
analysis was performed using DESeq2 considering as differentially activated all the
regions with a P adjusted ≤ 0.01 and a |log2FC| ≥ 2.
Active enhancer conservation across patients. A master list of active enhancer
regions across all PDOs was produced merging together the “Active Enhancer” and
“Flanking Active Enhancers” (Identification of active enhancers) states using
BEDTools60. Enhancer regions present in at least one patient were considered in
this analysis. To assess conservation, the enhancerome of each patient was inter-
sected with the master list of enhancers using a custom script in Python resulting in
a matrix that reported the presence (“1”) or absence (“0”) of each enhancer region
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across PDOs. To assess conservation, enhancers were stratified according to their
frequency across PDOs and further filtered for enhancers differentially activated
(gained) in PDOs compared to normal tissues.
Motif binding discovery. We performed motif discovery within the accessible
regions of the conserved gained enhancers. First, the ATAC-seq peak set for COAD
was downloaded from the TCGA site (https://gdc.cancer.gov/about-data/
publications/ATACseq-AWG/). To identify putative open chromatin regions
inside the most conserved enhancers, gained enhancer regions, conserved in at least
80% of the patients (n= 486), were overlapped with the COAD ATAC-seq peaks.
HOMER (v4.7)61 findMotifsGenome function was used to evaluate the enrichment
of known motifs in the exact size of the accessible regions (setting region size
parameter to “given”) compared to background sequences using the default
cumulative binomial distribution to score enrichment. Transcription factor binding
motifs encompassing the summit of TAZ peaks were identified with HOMER and
MEME-chip62 on 500 bp windows centered around TAZ peak summits.
Annotation of differentially activated enhancers. Differentially activated
enhancers were annotated to their putative interacting promoter region using
chromosome conformation capture (capture Hi-C) data on human CRC HT29 cell
line22. For gained enhancers not annotated with capture Hi-C, we selected and
merged all regions of the “Active TSS” and “Flanking active TSS” states for the ten
PDOs and the five normal tissue. Then, we identified all the protein-coding genes
(GENCODE Release 25 basic gene annotation) overlapping with the above active
promoter regions. (n= 13,802). Finally, we used the annotatePeakInBatch (output
= “both”, PeakLocForDistance= “middle”) function of ChIPpeakAnno (v3.12.7)63
to annotate active enhancers to their nearest protein-coding gene with an active
promoter.
Functional enrichment analysis. We used over-representation analysis based on
Fisher’s exact test to assess the functional enrichment of biochemical and signaling
pathways in the list of 495 tumor-upregulated genes annotated to gained enhan-
cers. Functional enrichment analysis was conducted in R using the fisher.test
function of the stats package on the 321 gene sets of the KEGG collection
(downloaded from ConsensusPathDB; http://cpdb.molgen.mpg.de/) considering a
genomic background of 21,528 unique gene symbols (given by the union of the
19,950 protein-coding genes of the human hg38 reference GENCODE Release 25
and of the genes of all KEGG gene sets). P-values have been adjusted (i.e., false
discovery rate) using the p.adjust function of R stats package and the threshold for
statistical significance set at FDR < 5%. The visualization of the functional
enrichment analysis results was obtained in Cytoscape64 using its EnrichmentMap
and AutoAnnotate applications (with default parameters).
ChIPmentation data processing and QC. ChIPmentation data was analyzed and
processed as described above (ChIP-seq data processing), with the difference that
adapters were removed before the alignment of the reads using BBDuk (command
line parameters: ktrim= r k= 23 mink= 11 hdist= 1; BBMap v38.16). Peaks were
called using MACS2 (v2.1.0)56, using as control the associated ChIPmentation on
the input control (command line parameters: --nomodel --extsize 200 -B -p 0.001).
P-values were corrected for multiple comparisons using the Benjamini–Hochberg
correction. Density plots and heatmaps were produced as described above (ChIP-
seq data processing), with the difference that the enrichment was performed on all
the promoter regions in GENCODE Release 25 basic gene annotation and the
active enhancer regions identified (n= 33,131).
Analysis of TAZ ChIPmentation data. TAZ peaks were overlapped with the
previously defined ChromHMM states using BEDTools, to assess the preferential
binding localization of TAZ in (i) all gained enhancers (G.E.) identified in PDOs,
(ii) the G.E. conserved in at least five patients, and (iii) those conserved in at least 8
patients. The BEDTools shuffle function was used to generate 1000 shuffle tracks
separately for each of the above G.E. subsets, preserving the number and size of
features in each of the G.E. subsets in the input BED file. Each feature in the input
BED file was repositioned in genomic regions of the ChromHMM-defined
enhancerome (n= 33,131 PDO and normal tissue enhancers), excluding the
genomic regions of PDO gained enhancers. In counting TAZ-bound regions, a
single count was considered for a region that overlapped multiple TAZ peaks. To
assess significance, we computed a one-sided empirical P-value by evaluating the
number of times the % of TAZ-bound reshuffled regions in a random set was as
extreme as the observed % of TAZ-bound enhancers in a specific G.E. subset,
divided by 1000 (number of permutations performed). None of the 1000 reshuffled
regions in each of the random sets had a percentage as high or higher than the
observed percentage of TAZ-bound enhancer regions in the corresponding G.E.
subset.
Analysis of TCGA pan-cancer ATAC-seq data. To identify potential pan-cancer
regulatory regions, pan-cancer ATAC-seq peak sets from the TCGA consortium
were used (https://gdc.cancer.gov/about-data/publications/ATACseq-AWG/)17.
The pan-cancer peakset was overlapped with the YAP/TAZ-bound gained
enhancers conserved in at least eight patients (n= 195). If multiple ATAC-seq
peaks were assigned to each enhancer only that with the highest normalized
enrichment score was considered. Then, the normalized ATAC-seq insertion
counts of the pan-cancer peak sets was downloaded from TCGA site (https://gdc.
cancer.gov/about-data/publications/ATACseq-AWG/) and was used to produce a
heatmap (pheatmap; clustering_distance_cols= euclidean, clustering_method=
complete) of all the TCGA patients and the 195 enhancer regions of interest. To
identify pan-cancer accessible regions, we performed hierarchical clustering with
cluster_rows= TRUE.
Analysis of publicly available H3K27ac ChIP-seq datasets. Publicly available
ChIP-seq data for H3K27ac were obtained from the Gene Expression Omnibus
(Supplementary Data 9). Raw sequencing reads were processed as described above
(ChIP-seq data processing). For each sample, the number of H3K27ac reads in the
consensus peakset of ~33 K active enhancers (Identification of active enhancers)
were counted in DiffBind. Read counts across samples were normalized and cor-
rected for potential batch effects using ComBat65. For each of the primary tumor
and normal tissue samples, the mean H3K27ac normalized counts across all 46
pan-cancer enhancer regions were calculated and the Wilcoxon rank sum test was
perfomed to determine the difference in H3K27ac intensities between primary
tumors and normal tissues.
Analysis of TCGA COAD RNA-seq data. The gene expression quantification
(HTSeq counts) and the clinical information for COAD were downloaded from the
R package TCGAbiolinks66 (https://bioconductor.org/packages/release/bioc/html/
TCGAbiolinks.html) (GDCquery(project= “TCGA-COAD”, data.category
= “Transcriptome Profiling”, data.type= “Gene Expression Quantification”, work-
flow.type= “HTSeq - Counts”). Both normal and tumor tissues were included in the
analysis while the Formalin-Fixed Paraffin-Embedded (FFPE) tissue specimens
were removed. The RNA-seq counts were normalized using DESeq2 as described
above. To retrieve the percentage of epithelial cells in normal and tumor samples,
decomposition of the bulk RNA-seq expression data was performed using
BisqueRNA67 (https://github.com/cran/BisqueRNA). The decomposition was
computed using default parameter and integrating scRNA-seq for 23 CRC primary
tissues32 previously annotated for major cell types (markers=NULL, use.overlap
= FALSE). To evaluate the expression level in epithelial cells, the COAD log2
normalized counts for target genes were multiplied for the epithelial cell proportion
as determined in BisqueRNA.
Single-cell RNA-seq data processing of primary CRCs. The raw count matrix of
3′ end scRNA-seq data (10X technology) on 63,689 cells from 23 CRC patients
consisting of 23 primary CRC and 10 matched normal mucosa samples were
downloaded from GSE132465. The matrix was then processed using the python
package Scanpy (v1.4.2)68. First, genes detected in <0.1% of the total cells and cells
with fewer than 200 expressed genes were removed. The total count matrix used for
downstream analysis was composed of 63,689 cells and 33,694 genes. The matrix
was normalised considering a scaling factor of 104 and log-transformed using
scanpy.pp.normalize_per_cell(data, counts_per_cell_after= 1e4) and scanpy.pp.
log1p(data). Highly variable genes (HVG) were selected based on specific thresh-
olds for mean expression and dispersion using scanpy.pp.highly_variable_genes
(min_mean= 0.08, max_mean= 4, min_disp= 0.7) and excluding mitochondrial
and ribosomal genes. The cell cycle phase of each cell was evaluated by scoring
individual cells for their expression of G1-, S-, and G2M-phase genes69.
Dimensionality reduction and clustering of scRNA-seq data. PCA was per-
formed on scaled and centered values considering 1093 HVG. Unwanted sources of
variation (i.e., number of detected counts and genes per cell, the percentages of
mitochondrial and ribosomal counts and the cell cycle phase) were evaluated and
regressed out using linear regression as implemented in scanpy (scanpy.pp.regress_-
out). Initially, a K-Nearest Neighbor graph was constructed based on Euclidean
distance in PCA space, thus refining the weight of the edges between two cells using
Jaccard similarity (scanpy.pp.neighbors with n_neighbors= 15, n_pcs= 15). For
reproducibility, we used the clustering annotation reported by the paper. T-Stochastic
Neighborhood Embedding (t-SNE) was used for visualization of the data. The
number of PCs used to calculate the embedding was the same as those used for the
clustering. Tumor and normal epithelial cells were isolated from the whole dataset of
CRC primary tissues and were analyzed using the same technical approach reported
above. The number of HVG used was 951, the number of neighbors was 15 and the
number of principal components was 20.
Scoring cells of primary CRCs using signature gene sets. Gene signature scores
were calculated (the equation is shown below) given a cell by gene expression
matrix and a geneset G. For each cell C in the matrix, the fraction of genes from G
that are expressed (expression levels > 0) is computed (2). Similarly, an expression
score for each cell C is evaluated by summing up the expression levels of genes
from G and dividing by the total sum of gene expression levels for all genes in the
same cell (3). The two scores are then multiplied together to yield a combined score
for each cell C (4) and the reciprocal of the negative logarithm of the combined
score is computed. Combined scores were created for a stemness gene set
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(Supplementary Data 10) and the gene set related to the 46 pan-cancer enhancers
(Supplementary Data 8).
Given a cell C defined as a vector of gene expression values ½gi; ¼ ; gC 
and a geneset G ¼ fg1; ¼ ; gGg
a coexpression score is calculated as:
c score ¼ ∑g2G½Cg > 0jGj ð2Þ
and an expression score is defined as:
e score ¼ ∑g2GCg
∑C
ð3Þ
The two scores are then combined to yield a combined score:
combined score ¼ c score  e score ð4Þ
Statistics and reproducibility. Statistical analyses were performed in R (v3.5.1)
and graphing in Illustrator (v25.0). Statistical significance was tested with a two-
sided Wilcoxon rank sum test for gene expression comparisons, and one-sided
Mann–Whitney U or Wilcoxon signed rank exact tests for organoid cell viability.
P-values are reported in each figure and legend. Results in Fig. 4b and Supple-
mentary Fig. 5f are representative of three independent repeats and in Fig. 4i for
three and six independent organoid lines for normal or tumoral PDOs,
respectively.
Reporting summary. Further information on experimental design is available in the
Nature Research Reporting Summary linked to this paper.
Data availability
The RNA-seq data used in this study are available in the European Nucleotide Archive
(ENA) database under accession code E-MTAB-8448. The ChIP-seq data generated in
this study have been deposited in the ENA database under accession code E-MTAB-
8416. The epigenomic (ChIP-seq on histone marks and ChromHMM tracks) and
transcriptomic (RNA-seq) data for all the PDOs analyzed in this study are publicly
available at the HePIC web browser at https://bioinformatics.ifom.eu/hepic/. Publicly
available datasets used in this study can be found in the Gene Expression Omnibus
(GEO) database under accession codes GSE77737 (colon; H3K27ac ChIP-seq),
GSE132465 (colorectal cancer; single-cell RNA-seq), GSE51776 (gastric cancer, H3K27ac
ChIP-seq), GSE114737 (breast and endometrial cancer; H3K27ac ChIP-seq), GSE74230
(osteosarcoma; H3K27ac ChIP-seq), GSE101065 (uterus; H3K27ac ChIP-seq),
GSE142924 (uterus; H3K27ac ChIP-seq), GSE16256 (liver, adrenal gland and pancreas;
H3K27ac ChIP-seq), GSE96504 (liver; H3K27ac ChIP-seq), GSE101019 (adrenal gland;
H3K27ac ChIP-seq), GSE95966 (adrenal gland; H3K27ac ChIP-seq), GSE101258
(thyroid gland; H3K27ac ChIP-seq), GSE96258 (thyroid gland; H3K27ac ChIP-seq),
GSE95981 (thyroid gland; H3K27ac ChIP-seq), GSE142995 (thyroid gland; H3K27ac
ChIP-seq), GSE101269 (pancreas; H3K27ac ChIP-seq), GSE101231 (pancreas; H3K27ac
ChIP-seq), GSE142968 (pancreas; H3K27ac ChIP-seq), GSE96212 (pancreas; H3K27ac
ChIP-seq). The remaining data are available within the Article, Supplementary
Information or available from the authors upon request. Source data are provided with
this paper.
Code availability
The code used in this study has been deposited on GitHub (https://github.com/
paganilab/DellaChiara_et_al_2021) and linked to the Zenodo Digital Repository
(https://doi.org/10.5281/zenodo.4588460)70.
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